Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma

Journal of Pathology

Volumn 189, Issue 4, 1999, Pages 552-558

  Kunz, M ^a   Toksoy, A ^a   Goebeler, M ^a   Engelhardt, E ^a   Brocker E B ^a   Gillitzer, R ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Chemokines; Immunology; IP 10; Malignant melanoma; Mig; Tumour infiltrating leukocytes

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE; INTERLEUKIN 8; MACROPHAGE CHEMOTACTIC FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; T LYMPHOCYTE; TISSUE DISTRIBUTION;

CHEMOKINES, CXC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERFERON TYPE II; INTERLEUKIN-1; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MELANOMA; NEOPLASM PROTEINS; RNA, MESSENGER; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032696574     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I     Document Type: Article

References (24)

1. thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 1996; 97: 279-284.
2. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996; 8: 628-636.
3. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4: 321-327.
4. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705.
5. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301-1314.
6. Farber JM. Mig and IP-10. CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-257.
7. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SK. The role of CXC chemokines as regulators of angiogenesis. Shock 1995; 4: 155-160.
8. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-162.
9. Sgadari C, Angiolillo AL, Cherney BW, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A 1996; 93: 13791-13796.
10. Sgadari C, Farber JM, Angiolillo AL, et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 1997; 89: 2635-2643.
11. Ritter U, Moll H, Laskay T, et al. Differential expression of chemokines in patients with localized and diffuse cutaneous American leishmaniasis. J Infect Dis 1996; 173: 699-709.
12. Goebeler M, Yoshimura T, Toksoy A, Ritter U, Bröcker EB, Gillitzer R. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol 1997; 108: 445-451.
13. Engelhardt E, Toksoy A, Goebeler M, Debus S, Bröcker EB, Gillitzer R. The chemokines IL-8, GROa, MCP-1, IP-10 and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol 1998; 153: 1849-1860.
14. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.
15. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101: 746-757.
16. Kanegane C, Sgadari C, Kanegane H, et al. Contribution of the CXC chemokine IP-10 and Mig to the anti-tumor effects of IL-12. J Leukoc Biol 1998; 64: 384-392.
17. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 1998; 161: 927-932.
18. Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, van Meir EG. Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 1997; 8: 1201-1212.
19. Rowley MJ, Cockerell CJ. Reliability of prognostic models in malignant melanoma. A 10-year follow-up study. Am J Dermatopathol 1991; 13: 431-437.
20. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol 1988; 133: 419-423.
21. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991; 11: 3125-3131.
22. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine transfer enhances antitumor immunity. Nature Med 1996; 10: 1090-1095.
23. Rösl F, Lengert M, Albrecht J, et al. Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids. J Virol 1994; 68: 2142-2150.
24. Kunz M, Hartmann A, Flory E, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential medianism for high tumor aggressiveness. Am J Pathol 1999; 155: (in press).